MedPath

SUBSTRATE HD

🇫🇷France
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

7

Active:1
Completed:3

Trial Phases

1 Phases

Not Applicable:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Not Applicable
3 (100.0%)

Long-Term Evaluation of TAILORED Vs Anatomical Ablation Strategy for Persistent Atrial Fibrillation

Recruiting
Conditions
Atrial Fibrillation
First Posted Date
2025-02-13
Last Posted Date
2025-03-13
Lead Sponsor
Volta Medical
Target Recruit Count
278
Registration Number
NCT06825104
Locations
🇫🇷

CHU Lyon, Hôpital Louis Pradel, Bron, France

🇫🇷

Pôle Santé République, Clermont-Ferrand, France

🇫🇷

Hôpital Saint Philibert, Lomme, France

and more 10 locations

Clinical and Healthcare Economic OutcoMes From ReAl-worlD Use in Europe of an AI Software During AF Ablation

Recruiting
Conditions
Atrial Fibrillation
Arrhythmias, Cardiac
Atrial Arrhythmia
First Posted Date
2023-10-13
Last Posted Date
2024-10-07
Lead Sponsor
Volta Medical
Target Recruit Count
150
Registration Number
NCT06083012
Locations
🇫🇷

Hôpital Privé Jacques Cartier, Massy, France

🇫🇷

Polyclinique Saint George, Nice, France

🇫🇷

Centre Cardiologique du Nord, Saint-Denis, France

and more 4 locations

Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation

Recruiting
Conditions
Atrial Fibrillation
First Posted Date
2023-09-28
Last Posted Date
2025-07-03
Lead Sponsor
Volta Medical
Target Recruit Count
400
Registration Number
NCT06056271
Locations
🇺🇸

Endeavor Health, Evanston, Illinois, United States

🇺🇸

Kansas City Cardiac Arrhythmia Research LLC, Overland Park, Kansas, United States

🇺🇸

Northwell Health, New York, New York, United States

and more 1 locations

Re-Ablation Using a Tailored Approach Targeting EGM-Dispersion

Not Applicable
Active, not recruiting
Conditions
Atrial Fibrillation
First Posted Date
2022-07-28
Last Posted Date
2025-07-02
Lead Sponsor
Volta Medical
Target Recruit Count
92
Registration Number
NCT05477147
Locations
🇺🇸

Grandview Medical Center, Birmingham, Alabama, United States

🇺🇸

Arrhythmia Research Group, Jonesboro, Arkansas, United States

🇺🇸

Ascension St. Vincent's Hospital, Jacksonville, Florida, United States

and more 16 locations

AutoMatic disPERsion Tagging Function Preliminary Evaluation

Not Applicable
Completed
Conditions
Atrial Fibrillation
Atrial Tachycardia
Atrial Arrhythmia
First Posted Date
2022-05-05
Last Posted Date
2023-11-22
Lead Sponsor
Volta Medical
Target Recruit Count
40
Registration Number
NCT05362656
Locations
🇫🇷

Hôpital Saint-Joseph, Marseille, France

  • Prev
  • 1
  • 2
  • Next

News

AI-Guided Cardiac Ablation Shows Superior Results in Landmark Persistent AF Trial

Volta Medical's AI-guided cardiac ablation combined with pulmonary vein isolation demonstrated 88% freedom from atrial fibrillation at 12 months, compared to 70% with standard treatment alone.

AI-Guided Ablation Shows Superior Results in Treating Persistent Atrial Fibrillation

A groundbreaking clinical trial demonstrates that AI-guided cardiac ablation combined with pulmonary vein isolation achieves 88% success rate in treating persistent atrial fibrillation, compared to 70% with standard treatment alone.

Clinical Trial Highlights: Advances in IPF, Diabetes, COPD, and Cancer Therapies

Arecor Therapeutics' AT278 demonstrated an accelerated PK/PD profile in overweight and obese individuals with Type 2 diabetes, showing promise for improved glucose control.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.